AFP and neoplasm: Researchers have developed other serum tumor markers for clinical use, including AFP-L3%, lectin-bound AFP, and PIVKA-II (protein induced by vitamin K absence or antagonists-II); however, those markers are unable to detect small HCC tumors in roughly 30% of patients [13].